Great Point Partners (GPP) has completed a growth investment in iXCells Biotechnologies, according to a news release.

iXCells, based in San Diego, is a provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide. Founded in 2014, the company focuses on primary and induced pluripotent stem cell-derived cellular models.

GPP, based in Greenwich, Conn., is a private investment firm focused on the healthcare industry. Founded in 2003, the firm targets investments in biopharmaceutical supply chain services and products; healthcare services; healthcare information technology-enabled services; and medical devices and diagnostics in businesses operating in the United States, Canada and Western Europe. GPP pursues companies generating between $10 million and $100 million of revenue and $2 million to $12 million of EBITDA, with equity investments ranging from $7 million to $50 million.

Terms of the investment were not disclosed.

One Equity Partners (OEP) has announced it has completed the acquisition of Prime Time Healthcare.

Prime Time, based in Omaha, Neb., is a healthcare staffing services provider. Founded in 2012, the company states that it provides placement services for registered nurses, licensed practical nurses, certified nursing assistants and allied health clinicians to approximately 8,500 U.S. facilities.

OEP, based in New York, is a middle market private equity firm. Founded in 2001 and spun out of J.P. Morgan in 2015, OEP seeks control-oriented investments with flexible structure in companies with revenue between $100 million and $800 million and EBITDA of $10 million to $70 million.

Terms of the acquisition were not disclosed.

Goldman Sachs Group has closed a $9.7 billion private equity fund, according to a Reuters report.

Through the fund, “West Street Capital Partners VIII,” the investment bank plans to invest an average of $300 million to take controlling stakes in companies in healthcare and other sectors.

Goldman Sachs stated that it intends to target companies with an enterprise value of about $750 million to $2 billion. The fund has already invested in Paraxel, a Newton, Mass.-based clinical research organization and a European pharmaceutical company, among others.

BlackRock Long Term Private Capital (LTPC) will acquire Paradigm Oral Health from shareholders including InTandem Capital Partners, according to a news release.

Paradigm, based in Lincoln, Neb., is an oral surgery and digital dentistry platform. Founded in 2018, the company states that it has partnered with more than 100 surgeons who provide care in 75 facilities throughout the United States.

LTPC is a direct private equity strategy backed by BlackRock that makes $500 million-plus control-focused investments in companies across North America and Western Europe.

InTandem, based in New York, focuses on acquiring middle market healthcare and insurance companies. Founded in 2011, the firm prefers to make more substantial investments from a dollars perspective in the provider services and non-reimbursement industries.

Terms of the acquisition were not disclosed.

Waud Capital Partners (WCP) has announced it has completed the sale of GI Alliance (GIA).

GIA, based in Southlake, Texas, is a gastroenterology practice management company. Founded in 2018 and formed in partnership with WCP, GIA states that it provides services to nearly 700 independent gastroenterologists operating in Texas, Arkansas, Arizona, Colorado, Florida, Illinois, Indiana, Kansas, Louisiana, Mississippi, Missouri, Oklahoma, Utah and Washington.

WCP, founded in 1993 and based in Chicago, seeks control equity investments in middle market companies in healthcare and a few other industries. Within healthcare, the firm targets the provider services, hospitals/major facilities, life sciences/pharmaceutical and non-reimbursement industries.

The transaction was facilitated by an investment from funds managed by global alternative asset manager Apollo and valued GIA at $2.2 billion.

Latticework Capital Management has announced its acquisition of Catalina Research Institute (CRI).

CRI, based in Montclair, Calif., is a multidisciplinary clinical trials facility. Founded in 1997, the company specializes in the conduct of phase II through phase IV pharmaceutical drug studies.

Latticework, based in Dallas, makes control equity investments in the lower middle market. Founded in 2015, the firm focuses exclusively on healthcare, specifically the provider services, hospital/major facilities, life sciences/pharmaceutical (pharmaceutical services and contract manufacturing for medical equipment/devices) and non-reimbursement industries. Latticework prefers to make more substantial investments from a dollars perspective.

Terms of the acquisition were not disclosed.

Latticework also announced the formation of American Clinical Research Services Holdings, a clinical trial site management organization, via the acquisition of CRI.

WindRose Health Investors has announced it has completed an investment in Third Wave Recovery Systems (TWRx).

TWRx, based in Las Vegas, is a pharmaceutical rebate manager. The company provides services to hospitals, long-term care (LTC) facilities and select specialty physician groups.

WindRose, based in New York, pursues control equity investments in healthcare companies. Founded in 2000, the firm invests in a broad range of industry segments, including outsourced services to payors and health systems, technology-enabled services, healthcare providers and value-added distribution.

Terms of the investment were not disclosed.

In conjunction with WindRose’s investment, TWRx acquired SRX. Based in New York, SRX is a provider of pharmaceutical rebate management services for the skilled nursing and LTC industries.

Pharos Capital Group has announced it has invested in Renal Care 360°.

Renal Care 360°, based in Franklin, Tenn., is a nephrology practice and chronic care management company. Founded in 2018, the company partners with health systems, physician groups and local communities to provide community healthcare management services.

Pharos, with offices in Dallas and Nashville, pursues control equity and mezzanine investments in lower and middle market companies primarily in healthcare and business services. Founded in 1998, the firm targets the provider services and non-reimbursement industries within healthcare.

Terms of the investments were not disclosed.

LLR Partners has announced a growth investment in Vantage Point Logistics (VPL).

VPL, based in Westerville, Ohio, is a provider of supply chain management software for healthcare organizations. Founded in 2011, the company states it works with more than 700 hospitals, pharmacies and ambulatory surgery centers and more than 6,000 suppliers.

LLR, based in Philadelphia and founded in 1999, invests in a targeted set of industries, with a focus on middle market technology and services businesses. Within healthcare, the firm pursues investments in healthcare IT, outsourced healthcare services, managed care and provider-based organizations.

Terms of the investment were not disclosed.

Shore Capital Partners will sell EyeSouth Partners to Olympus Corp. for just under $1 billion, Axios reports.

EyeSouth, based in Atlanta, is a network of eye care practices located throughout the country. Founded in 2017, the company states its network consists of more than 30 practices with over 250 doctors who provide care at approximately 150 locations, including 19 surgery centers.

Shore Capital Partners, based in Chicago, pursues healthcare investments in the lower middle market. Founded in 2009, the firm pursues control equity investments in the healthcare services, products and distribution markets through a range of investment amounts. Within healthcare, Shore seeks to invest in the provider services and non-reimbursement industries.

Olympus, which is based in Tokyo, Japan, and has its U.S. headquarters in Center Valley, Pa., is a global manufacturer of optical and digital technology.